Russ Cohen

Galera Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying







Insider Stock Purchases: A Closer Look at Recent Transactions

Insiders Making Moves

As the Dow Jones index took a slight dip by over 50 points at the market’s close on Monday, insider actions within companies often serve as a litmus test of faith or skepticism in a company’s future. For observers interested in penny stocks, these insider dealings can paint a vivid backdrop to consider when making investment decisions.

Let’s delve into a few recent noteworthy insider transactions in the realm of penny stocks. For a more extensive overview, be sure to peruse Benzinga’s insider transactions platform.

A Shrewd Acquisition by AmeriServ Financial

  • The Deal: AmeriServ Financial, Inc. ASRV Director Richard W. Bloomingdale scooped up a total of 1,783 shares at an average price of $2.85, amounting to an investment of approximately $5,086.
  • Recent Developments: On Jan. 23, AmeriServ Financial reported a loss for the fourth quarter.
  • AmeriServ Financial’s Focus: AmeriServ Financial Inc is a bank holding company primarily earning revenue from banking, bank-related services, and trust-related services.

Dakota Gold Digs Deeper

  • The Purchase: Dakota Gold Corp. DC Director Alice D. Schroeder secured 7,410 shares at an average price of $1.96, expending around $14,521.
  • Recent Events: On Feb. 21, Dakota Gold unveiled additional results for twelve drill holes from the Richmond Hill Gold Project.
  • Dakota Gold’s Mission: Dakota Gold Corp is a gold exploration and development company with a keen focus on revitalizing the Homestake District in Lead, South Dakota, boasting high-quality gold mineral properties across over 40 thousand acres around the historic Homestake Mine.

Don’t Miss: Macy’s, Lowe’s and 3 Stocks to Keep an Eye on Heading into Tuesday

Galera Therapeutics Gains Momentum

  • The Deal: Galera Therapeutics, Inc. GRTX 10% owner Yair Schneid obtained 932,402 shares at an average price of $0.18, investing around $166,417 into the company.
  • Recent Advances: On Nov. 14, Galera Therapeutics reported a narrower-than-expected loss in the third quarter.
  • Galera Therapeutics’ Focus: Galera Therapeutics Inc is a biopharmaceutical entity dedicated to developing and bringing to market an array of novel, proprietary therapeutics poised to revolutionize cancer radiotherapy.
See also  The Impact of Trump's Policies on the Magnificent Seven StocksTrump's Potential Impact on the Magnificent Seven Companies

In the annals of American history, only one former president has managed to secure reelection after losing the first term - Grover Cleveland in 1892, a solitary figure in this political parable. Fast forward to the present, where former President Donald Trump is in a neck-and-neck race with Vice President Kamala Harris for the 2024 presidential throne. Should Trump emerge victorious, his policy decisions could cast a long shadow on the fortunes of the revered "Magnificent Seven" companies that include tech behemoths like Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, and Tesla. An intriguing narrative unfolds as investors weigh their options in this high-stakes drama.

Former President Donald Trump. Image source: Official White House Photo by Shealah Craighead.

Assessing Trump's Proposals and Their Ramifications

A trio of Trump's propositions loom large over the future of the Magnificent Seven, with his corporate tax cut scheme taking center stage. If re-elected, Trump vows to slice the federal corporate tax rate from the current 21% to a paltry 15%, a move that could recalibrate the financial landscape for these titans of industry. Tariffs are another cornerstone of his economic blueprint, with up to 20% levies on imports and a spotlight on China evident in his rhetoric. Moreover, Trump's zeal for deregulation, epitomized by a promise to scrap onerous rules at a 10:1 ratio against new regulations, could create seismic shifts, especially around artificial intelligence governance.

Forecasting the Corporate Weather for the Magnificent Seven

While a reduced tax burden might sound like sweet music to the ears of the Magnificent Seven, a deeper dive reveals a nuanced backdrop. Unveiling the effective tax rates paid by these giants in the last fiscal year paints a revealing picture. Alphabet, Amazon, Apple, Meta Platforms, Microsoft, and Nvidia all operate below the current 21% threshold, with Tesla even benefiting from a 50% tax boon, making the tax cut impact a mixed bag of fortunes.

Trump's tariff barrage could rattle the foundations of reliant companies, stirring debates on cost pass-through to consumers and the resultant sales pendulum. Apple's global supply chain stands vulnerable to the tariff storm, though players like Alphabet and Meta, deriving significant revenue from services, might weather the storm better.

The shadow of deregulation could sway fortunes in the cloudy skies of AI governance. Amazon, Microsoft, Alphabet, Nvidia, and to a lesser extent, Meta and Tesla, stand to gain from relaxed regulations, shaping a turbulent yet potentially rewarding horizon.

Trump's pointed criticism of Alphabet and Meta, juxtaposed with his favorable stance towards Microsoft and Nvidia, sets the stage for a strategic showdown where winners and losers are yet to emerge from the fog of political warfare.

Identifying the Ripest Pick among the Magnificent Seven

As the curtain rises on the looming political drama, the quest for the choicest investment amidst the Magnificent Seven intensifies. Microsoft and Nvidia emerge as prime contenders in this investment battleground. While Microsoft could reap the fruits of Trump's tax cuts due to its high tax rate and navigate the tariff headwinds, Nvidia's growth potential offers a tantalizing allure, promising the elixir of prosperity beyond the mirage of political turbulence. In the tumultuous landscape of Trumpian economics, the astute investor's choice between these icons could unfold as a pivotal journey towards prosperity.

Investment Insights: Assessing the Timing of Lucrative Opportunities Investment Insights: Assessing the Timing of Lucrative Opportunities